What does the evidence show about Metformin's effects?

Read Off Label rates the evidence for Metformin as Strong and the benefit magnitude as variable, producing an overall grade of B+ (7.2/10). UKPDS showed 36% reduction in all-cause mortality in T2D.

What safety findings are reported for Metformin?

Metformin has a low-med risk profile in the database. Low-Med (GI side effects; B12 deficiency with chronic use; lactic acidosis rare; may blunt exercise adaptations) Legal status: Rx (off-label for longevity).

What doses or routes are reported for Metformin?

500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.

Rankings / Longevity — Pharma (Off-Label)

Metformin

Longevity · Biguanide

Also known as: Glucophage ·Glumetza ·Fortamet ·Riomet

Tier B+

Reviewed by Read Off Label · Last reviewed Jul 1, 2026 · How we grade

mtor-inhibitionampkmicrobiomebiguanideprescription

7.2 / 10

Tier B+

Ev 8 Bn 5 Sf 7

Bottom line

Read Off Label grades Metformin as B+ (7.2/10) based on strong evidence, variable benefit magnitude, and a low-med-risk safety profile.

UKPDS showed 36% reduction in all-cause mortality in T2D.

Studied, labeled, or reported-use context: 500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals — Rx; not individualized guidance.

If you were testing this on yourself

Two properties decide whether an n-of-1 experiment is readable and recoverable. These describe the experiment — they are not a judgment about whether to run it, and nothing here is a recommendation.

Can you undo it?

Reverses on stopping

Reversible. GI effects resolve on stopping and often on their own. B12 depletion from chronic use is correctable once identified, which is why it is worth measuring.

Can you tell if it worked?

Readable — Days on a CGM; 3 months for HbA1c

Fasting glucose, HbA1c, or a CGM. B12 on a panel after long-term use.

What would fool you For the longevity use rather than the glycaemic one, there is no readout at all — you would be measuring glucose as a proxy for something else entirely. Evidence that it blunts exercise adaptations means pairing it with a training block confounds both.

What the evidence says

UKPDS showed 36% reduction in all-cause mortality in T2D. TAME trial ($75M, 3000 non-diabetic older adults) repeatedly delayed — FDA approved design but unfunded. 2019 Konopka data: may blunt exercise-induced mitochondrial adaptations.

Mechanism

Complex I mild inhibition → AMPK activation → mTOR inhibition; improved insulin sensitivity; possible gut microbiome effects; reduced hepatic gluconeogenesis

Studied, labeled, or reported dose & route

500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Metformin's effects?: Read Off Label rates the evidence for Metformin as Strong and the benefit magnitude as variable, producing an overall grade of B+ (7.2/10). UKPDS showed 36% reduction in all-cause mortality in T2D.
What safety findings are reported for Metformin?: Metformin has a low-med risk profile in the database. Low-Med (GI side effects; B12 deficiency with chronic use; lactic acidosis rare; may blunt exercise adaptations) Legal status: Rx (off-label for longevity).
What doses or routes are reported for Metformin?: 500-2000 mg/day PO; clinical titration commonly begins at 500 mg with meals This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Metformin work?: Complex I mild inhibition → AMPK activation → mTOR inhibition; improved insulin sensitivity; possible gut microbiome effects; reduced hepatic gluconeogenesis

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.